£10m ($16.6 million) funding boost to eliminate elephantiasis globally

December 02, 2009

The Centre for Neglected Tropical Diseases (CNTD) at the Liverpool School of Tropical Medicine has been awarded £10 million by the UK Department for International Development (DFID) to support endemic countries in tackling lymphatic filariasis (LF) - a crippling disease more commonly known as elephantiasis.

The funding builds on earlier successful collaborations against lymphatic filariasis and will support programmes to reduce the prevalence of LF and other related neglected tropical diseases (NTDs) and make progress towards eventual elimination of LF. The award is part of a £50 million grant announced by the International Development Secretary, Douglas Alexander, to "wipe out deadly tropical diseases".

Elephantiasis is a parasitic infection that causes acute and chronic illness, disability and disfigurement in 81 countries in Asia-Pacific, Asia and the Americas. More than a billion people around the globe - 18% of the world's population - are at risk of contracting the disease. Forty million have clinical symptoms which are painful, seriously disfiguring and debilitating. LF prevents people from working and contributes to a vicious cycle of ill health and poverty.

The World Health Organization (WHO) recommends that LF infection can be prevented by treating entire endemic communities once a year with two co-administered anti-parasitic drugs for a minimum of five years. The impact of the drugs on other NTDs also brings other health benefits such as improved physical development among children and improved maternal and newborn health. The DFID grant will enable CNTD to support 12 countries to administer these drugs to more than one quarter of a billion people at risk of LF in these countries over the next five years.

Professor Moses Bockarie, Director of CNTD, said: "We have a real opportunity here to relegate LF to the history books. Since the LF elimination programme started a decade ago it has prevented more than seven million newborns from acquiring the disease, which would have resulted in more than two million clinical cases."

The grant, alongside ongoing joint financial support from GlaxoSmithKline (GSK), will also support the activities of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), a partnership of public and private sectors working towards LF elimination, and whose Secretariat is hosted at CNTD. GAELF is coordinating efforts with WHO and other disease control programmes and NTD partnerships.

"Tackling multiple infections as a group has allowed us to focus more on the rapid expansion of treatments to millions of people. Such an integrated, population-based approach also saves time, resources and reduces the burden to locally manage them," said Lorenzo Savioli, WHO Director of the Department of Control of Neglected Tropical Diseases.

DFID support complements substantial financial inputs for NTDs from the Gates Foundation and USAID, drug donations by GSK and Merck, and technical input by WHO.

"The remarkable progress in fighting LF demonstrates what we can do in the field of NTDs," said Andrew Witty, Chief Executive Officer of GSK. "Working together, we have a real possibility to eliminate a devastating disease and alleviate human suffering."
-end-


Liverpool School of Tropical Medicine

Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.